Aimmune Therapeutics Just Made History: Is It a Buy?
The food allergy specialist just landed its first approval.
Aimmune Therapeutics
AIMT
AIMT
$27.25
-$0.05
-0.2%
Price as of February 20, 2020, 10:15 a.m. EST
View Interactive AIMT Charts
Aimmune Therapeutics, Inc.
Interactive Chart
News & Analysis: Aimmune Therapeutics
What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
The FDA’s approval sets the company off on the right path as it advances in the treatment of food allergies.
FDA Approves First Drug for Peanut Allergy
The first approved drug for any food allergy may be the first of several from Aimmune Therapeutics.
Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients
An upcoming FDA decision on Aimmune’s first drug could set the tone for the rest of its pipeline.
4 Healthcare Stocks With FDA Approvals on the Horizon
With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.
20 Stocks That Could Double Your Money in 2020
Big gains could be just a click of the buy button away.
Aimmune Therapeutics Inc (AIMT) Q3 2019 Earnings Call Transcript
AIMT earnings call for the period ending September 30, 2019.
Here's Why Aimmune Therapeutics Stock Jumped on Wednesday
A survey of allergists suggests Palforzia's launch could be more successful than expected.
Will Vaping Deaths Derail Marijuana Stocks? Plus, a New Treatment for Peanut Allergies Advances
How vaping risks may impact cannabis companies and Aimmune Therapeutics' plan to change how doctors treat peanut allergies.
Did the FDA Just Signal Smooth Sailing Ahead For Aimmune Therapeutics?
Here's what a benign briefing document means, and what it doesn't.
